Success Metrics

Clinical Success Rate
88.6%

Based on 350 completed trials

Completion Rate
89%(350/395)
Active Trials
188(25%)
Results Posted
15%(53 trials)
Terminated
45(6%)

Phase Distribution

Ph early_phase_1
10
1%
Ph phase_1
19
2%
Ph phase_3
13
2%
Ph phase_4
7
1%
Ph phase_2
41
5%
Ph not_applicable
247
32%

Phase Distribution

29

Early Stage

41

Mid Stage

20

Late Stage

Phase Distribution337 total trials
Early Phase 1First-in-human
10(3.0%)
Phase 1Safety & dosage
19(5.6%)
Phase 2Efficacy & side effects
41(12.2%)
Phase 3Large-scale testing
13(3.9%)
Phase 4Post-market surveillance
7(2.1%)
N/ANon-phased studies
247(73.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.1%

350 of 421 finished

Non-Completion Rate

16.9%

71 ended early

Currently Active

188

trials recruiting

Total Trials

763

all time

Status Distribution
Active(242)
Completed(350)
Terminated(71)
Other(100)

Detailed Status

Completed350
Recruiting124
unknown97
Active, not recruiting64
Not yet recruiting50
Terminated45

Development Timeline

Analytics

Development Status

Total Trials
763
Active
188
Success Rate
88.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 110 (3.0%)
Phase 119 (5.6%)
Phase 241 (12.2%)
Phase 313 (3.9%)
Phase 47 (2.1%)
N/A247 (73.3%)

Trials by Status

not_yet_recruiting507%
active_not_recruiting648%
enrolling_by_invitation41%
terminated456%
completed35046%
withdrawn263%
unknown9713%
recruiting12416%
suspended30%

Recent Activity

Clinical Trials (763)

Showing 20 of 763 trialsScroll for more
NCT07160621Not Applicable

Culturally Adapted Mobile Treatment of Chronic Pain in Adolescent Survivors of Pediatric Cancer: A Randomized Clinical Trial

Recruiting
NCT07602374Not Applicable

Efficacy of Written Versus Video Patient Education Materials for Postmastectomy Breast Reconstruction

Recruiting
NCT06478849

Adherence and Understanding of a Therapeutic Education Program for Patients With Central Venous Access (EDUVVC)

Completed
NCT04070950

Sexuality of Women With Pelvic Cancer

Completed
NCT07639320Not Applicable

Benefits of Using Virtual Reality Preoperatively in Managing Anxiety During Outpatient Foot Bone Surgery

Terminated
NCT07640373Not Applicable

Coping Strategies, Loneliness, and Resilience in Patients With Dermatosis

Not Yet Recruiting
NCT07499518

Fertility and Polycystic Ovary Syndrome

Not Yet Recruiting
NCT05969457Phase 3

Effect of Preventive Analgesia by Injection of a Local Anesthetic Before Vaginal Incision for Hysterectomy by vNOTES Approach

Recruiting
NCT02263014

Psychosocial Outcomes and Contralateral Prophylactic Mastectomy (CPM)

Active Not Recruiting
NCT05207098

A Study of Neurocognitive Tests and Questionnaires for People With Head and Neck Cancer Who Are Undergoing Radiation Therapy

Recruiting
NCT07631026Not Applicable

Wearable Device Tracked Recovery From Autologous Breast Reconstructive Surgery

Not Yet Recruiting
NCT07629167Phase 2

Isotretinoin vs. Doxycycline for Acneiform Rash in Patients Receiving Drugs That Target the MAPK Pathway

Not Yet Recruiting
NCT07627490Not Applicable

The Potential of Transcutaneous Electrical Nerve Stimulation to Improve Pain Experienced During Posterior Branch Blocks in Patients With Lumbar Posterior Joint Syndrome

Not Yet Recruiting
NCT07443800Not Applicable

Comorbidity Between Attention Deficit Hyperactivity Disorder and Fibromyalgia

Not Yet Recruiting
NCT07623096

EMBRACE- BLOOM - Building Literacy and Outcomes Through Observation and Monitoring: Information Needs and Wearable Data in Pregnancy Couples

Not Yet Recruiting
NCT05056077Not Applicable

Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)

Active Not Recruiting
NCT05048459Not Applicable

Comparing Two Surveillance Approaches for People Who Have Received Treatment for HPV-associated Head and Neck Cancer and Show No Signs of Disease

Active Not Recruiting
NCT03429907Not Applicable

An Early Stress-Reduction Intervention in Patients With Newly Diagnosed Breast Cancer

Active Not Recruiting
NCT05681039Phase 2

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

Active Not Recruiting
NCT07622095

Validation of the French Version of the New Mobility Score (NMS)

Not Yet Recruiting

Drug Details

Intervention Type
OTHER
Total Trials
763